Insilico Medicine gets FDA approval for ISM8969, NLRP3 inhibitor. Phase I trial in US to assess safety, tolerability.
Approval of the Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA) has opened the door for the ISM8969 clinical trial in the United States. This Phase I study is set to assess the safety, tolerability, and pharmacokinetics of ISM8969, a new oral therapeutic. The approval marks an important milestone, allowing the trial to move forward and potentially benefit patients.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments